Search | Clinical Trials Finder

Conditions: Venous Thromboembolism, Deep Venous Thrombosis
Interventions: Percutaneous mechanical thrombectomy (PMT); Device
Lead sponsor: Inari Medical; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 15
States / cities: Newport Beach, California • New Haven, Connecticut • Miami, Florida + 12 more

Conditions: Deep Venous Thrombosis, Pulmonary Embolism
Interventions: Low dose nadroparin, Intermediate dose nadroparin, Low dose enoxaparin, Intermediate dose enoxaparin, Low dose dalteparin, Intermediate dose dalteparin, Fixed low dose tinzaparin, Intermediate dose tinzaparin; Drug
Lead sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA); Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 1,110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Embolism, Thrombophlebitis
Interventions: Recombinant Tissue Plasminogen Activator, Heparin, Warfarin; Drug
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Thromboembolism
Interventions: IWPC adapted genotype-guided dosing algorithm for warfarin, Modified IWPC genetic-guided warfarin dosing algorithm, Standard of care treatment; Genetic · Other
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 2,415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Prostate Cancer, Venous Thromboembolism, Lymphocele After Surgical Procedure, Deep Venous Thrombosis, Pulmonary Embolism
Interventions: Subcutaneous Heparin; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 501 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Atrial Fibrillation, Deep Vein Thrombosis, Dilated Cardiomyopathies
Interventions: Financial Incentive and Med-eMonitor, 2Med-eMonitor; Behavioral · Device
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Deep Vein Thrombosis, Pulmonary Embolism
Interventions: Discontinue anticoagulant therapy (Negative d-dimer), Continue on anticoagulant therapy (positive d-dimer); Other
Lead sponsor: McMaster University; Other
Eligibility: 18 Years to 75 Years
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2016
U.S. locations: 7
States / cities: Washington D.C., District of Columbia • Iowa City, Iowa • Boston, Massachusetts + 3 more

Conditions: Deep Vein Thrombosis, Pulmonary Embolus
Interventions: Rivaroxaban, Enoxaparin; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 149,248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Deep Venous Thrombosis
Interventions: Not listed
Lead sponsor: Swanson Center; Other
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2022
U.S. locations: 1
States / cities: Leawood, Kansas

Conditions: Pulmonary Embolism, Deep Vein Thrombosis, Cancer, Surgery
Interventions: Human Alert; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 2,496 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 26
States / cities: Scottsdale, Arizona • Long Beach, California • Orange, California + 22 more

Conditions: Post Thrombotic Syndrome, Deep Vein Thrombosis, Venous Stasis Syndrome, Venous Insufficiency, Postphlebitic Syndrome
Interventions: VeinOPlus; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Venous Thromboembolism, Pulmonary Embolism, Deep Vein Thrombosis, Cancer, Surgery
Interventions: Exposure to clinical decision support system and education; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Deep Vein Thrombosis, Pulmonary Embolism, Venous Thromboembolism
Interventions: Apixaban 2.5 MG, Placebo oral tablet; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Deep Venous Thrombosis
Interventions: Not listed
Lead sponsor: Sir Mortimer B. Davis - Jewish General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 803 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2012
U.S. locations: 3
States / cities: Detroit, Michigan • Durham, North Carolina • Oklahoma City, Oklahoma

Conditions: Venous Thrombosis, Neoplasms
Interventions: Heparin, Low-Molecular-Weight, or direct oral anticoagulants; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2022
U.S. locations: 3
States / cities: Minneapolis, Minnesota • Columbus, Ohio • Milwaukee, Wisconsin

Conditions: Venous Leg Ulcers
Interventions: HP802-247, Vehicle; Biological
Lead sponsor: Healthpoint; Industry
Eligibility: 18 Years and older
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 37
States / cities: Phoenix, Arizona • Carlsbad, California • Castro Valley, California + 32 more

Conditions: Deep Venous Thrombosis, Pulmonary Embolism
Interventions: Dabigatran: extended treatment (e.g at least 90 days), Dabigatran: extended treatment (e.g at least 180 days), Dabigatran: extended treatment (e.g at least 270 days), Apixaban: extended treatment (e.g at least 90 days), Apixaban: extended treatment (e.g at least 180 days), Apixaban: extended treatment (e.g at least 270 days), Rivaroxaban: extended treatment (e.g at least 90 days), Rivaroxaban: extended treatment (e.g at least 180 days), Rivaroxaban: extended treatment (e.g at least 270 days), Edoxaban: extended treatment (e.g at least 90 days), Edoxaban: extended treatment (e.g at least 180 days), Edoxaban: extended treatment (e.g at least 270 days), Warfarin: extended treatment (e.g at least 90 days), Warfarin: extended treatment (e.g at least 180 days), Warfarin: extended treatment (e.g at least 270 days); Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 416,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pulmonary Embolism, Venous Thromboembolism, Deep Vein Thrombosis
Interventions: Not listed
Lead sponsor: Volcano Corporation; Industry
Eligibility: 19 Years to 85 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Atlanta, Georgia • Raleigh, North Carolina • Knoxville, Tennessee

Conditions: Venous Thromboembolism
Interventions: Rivaroxaban (Xarelto, BAY59-7939), Placebo; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,197 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 25
States / cities: Little Rock, Arkansas • Los Angeles, California • Redlands, California + 20 more

Conditions: Venous Thromboembolism
Interventions: Not listed
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 7,797 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 19
States / cities: Long Beach, California • Miami, Florida • Pembroke Pines, Florida + 15 more

Conditions: Venous Thromboembolic Disease, Deep Vein Thrombosis, Pulmonary Embolism
Interventions: 5000 Units unfractionated Heparin Q 8 hr, 30mg enoxaparin Q12 hr; Drug
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years and older
Enrollment: 495 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: San Diego, California

Conditions: Cancer, Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Blood Clot
Interventions: Rivaroxaban, Apixaban, Edoxaban, Dabigatran, Warfarin, Dalteparin, Enoxaparin, Fondaparinux; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years and older
Enrollment: 811 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 151
States / cities: Chula Vista, California • Fremont, California • Fresno, California + 104 more

Conditions: Acute Deep Venous Thrombosis of Ileofemoral Vein
Interventions: Thrombectomy; Device
Lead sponsor: Paul J. Gagne; Other
Eligibility: 18 Years to 89 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Darien, Connecticut • Hyannis, Massachusetts • Leominster, Massachusetts + 3 more

Conditions: Venous Thromboembolism, Traumatic Brain Injury
Interventions: enoxaparin, placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 2
States / cities: Dallas, Texas • Tyler, Texas

Search by objective public record fields.

The Protrieve PROTECTOR Study

Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy

Treatment for Blood Clots in the Veins of the Legs

Applying Pharmacogenetic Algorithms to Individualize Dosing of Warfarin

PREvention of VENous ThromboEmbolism Following Radical Prostatectomy

Randomized Trial of Interventions to Improve Warfarin Adherence

D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months

Emulation of the RECORD3 Trial Using Healthcare Claims Data

Doppler Ultrasound Imaging of Plastic Surgery Patients for DVT Detection

Multi-Center Human Alert Trial to Prevent DVT and PE

Pilot Study for VeinoPlus to Improve Symptoms of Postthrombotic Syndrome (PTS)

Intervention to Improve Utilization of Extended Venous Thromboembolism Prophylaxis After Cancer Surgery

Extended-Duration Low-Intensity Apixaban to Prevent Recurrence in High-Risk Patients With Provoked Venous Thromboembolism

Biomarker Sub Study of the Compression Stockings to Prevent the Post-Thrombotic Syndrome (SOX) Trial

Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis

Study Investigating the Safety and Efficacy of HP802-247 in the Treatment of Venous Leg Ulcers >12 cm2 to ≤ 36 cm2

The DARE Warfarin CER Study

Evaluation of the Short and Long Term Performance and Clinical Outcomes of the Crux Vena Cava Filter System

Once - Daily Oral Direct Factor Xa Inhibitor Rivaroxaban In The Long-Term Prevention Of Recurrent Symptomatic Venous Thromboembolism In Patients With Symptomatic Deep-Vein Thrombosis Or Pulmonary Embolism. The Einstein-Extension Study

RE-COVERY DVT/PE: Global Study on Treatment Secondary Prevention of Acute Venous Thromboembolism

Venous Thromboembolic Prophylaxis After Trauma: Three Times a Day Unfractionated Heparin Versus Twice a Day Enoxaparin

Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer

Post Market Registry Study of the Philips QuickClear Mechanical Thrombectomy System

Delayed Versus Early Enoxaparin Prophylaxis After Traumatic Brain Injury (TBI)